World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
23624
World Ranking
13776
National Ranking
6991

Ronald D. Alvarez publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ronald D. Alvarez sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 433 publications — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ronald D. Alvarez D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ronald D. Alvarez sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ronald D. Alvarez is affiliated with Vanderbilt University Medical Center in the United States and has contributed extensively to medical research, particularly in the intersections of oncology, reproductive medicine, and obstetrics and gynecology. Their work spans a total of 58 publications primarily in the field of medicine.

Their research covers several specialized subfields including:

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Gender Studies

Alvarez's main research topics include:

  • Ovarian cancer diagnosis and treatment
  • Diversity and Career in Medicine
  • Endometrial and Cervical Cancer Treatments
  • Intraperitoneal and Appendiceal Malignancies
  • PARP inhibition in cancer therapy
  • Social Media in Health Education
  • Health and Medical Research Impacts

The scientist has authored papers published in multiple high-impact venues. Frequently published journals include:

  • Gynecologic Oncology
  • American Journal of Obstetrics and Gynecology
  • Journal of the National Comprehensive Cancer Network
  • Gynecologic Oncology Reports
  • UNC Libraries

Notable recent publications by Alvarez include:

  • Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, 2021, Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022, 2022, Journal of the National Comprehensive Cancer Network
  • NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024, 2024, Journal of the National Comprehensive Cancer Network
  • Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer, 2020, Gynecologic Oncology
  • Early resynchronization of non-pregnant beef cows based in corpus luteum blood flow evaluation 21 days after Timed-AI, 2020, Theriogenology

Alvarez has collaborated frequently with several researchers, indicating a network of professional co-authorships. Frequent co-authors include:

  • Marta A. Crispens
  • Charles A. Leath
  • Barbara A. Goff
  • Deborah K. Armstrong
  • Premal H. Thaker

Best Publications

  • Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

    Tyler J Curiel;Shuang Wei;Haidong Dong;Xavier Alvarez

  • Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study

    Franco M. Muggia;Patricia S. Braly;Mark F. Brady;Gregory Sutton

  • Adenocarcinoma of the Endometrium: Survival Comparisons of Patients with and without Pelvic Node Sampling

    Larry C. Kilgore;Edward E. Partridge;Ronald D. Alvarez;J.Maxwell Austin

  • Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group

    J. Tate Thigpen;Mark F. Brady;Ronald D. Alvarez;Mark D. Adelson

  • Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

    Maurie Markman;P.Y. Liu;Sharon Wilczynski;Bradley Monk

  • Ovarian cancer, version 2.2020

    Deborah K. Armstrong;Ronald D. Alvarez;Jamie N. Bakkum-Gamez;Lisa Barroilhet

  • Stem cell pathways contribute to clinical chemoresistance in ovarian cancer

    Adam D. Steg;Kerri S. Bevis;Ashwini A. Katre;Angela Ziebarth

  • Targeting Adenovirus to the Serotype 3 Receptor Increases Gene Transfer Efficiency to Ovarian Cancer Cells

    Anna Kanerva;Galina V. Mikheeva;Victor Krasnykh;Candace J. Coolidge

  • Ovarian cancer, version 1.2016: Clinical practice guidelines in oncology

    Robert J. Morgan;Deborah K. Armstrong;Ronald D. Alvarez;Jamie N. Bakkum-Gamez

  • Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix

    Ronald D. Alvarez;Seng-Jaw Soong;Walter K. Kinney;Gary C. Reid

  • NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

    Deborah K Armstrong;Ronald D Alvarez;Jamie N Bakkum-Gamez;Lisa Barroilhet

  • Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.

    Ronald D. Alvarez;Edward E. Partridge;M.B. Khazaeli;Gene Plott

  • Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.

    Anna Kanerva;Minghui Wang;Gerd J. Bauerschmitz;John T. Lam

  • Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.

    Gerd J. Bauerschmitz;John T. Lam;Anna Kanerva;Kaori Suzuki

  • Differences in Immune Responses Induced by Oral and Rectal Immunizations with Salmonella typhi Ty21a: Evidence for Compartmentalization within the Common Mucosal Immune System in Humans

    A. Kantele;A. Kantele;M. Häkkinen;M. Häkkinen;Z. Moldoveanu;A. Lu

  • Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.

    Anna Kanerva;Kurt R Zinn;Tandra R Chaudhuri;John T Lam

  • A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.

    Ronald D. Alvarez;Mack N. Barnes;Jesus Gomez-Navarro;Minghui Wang

  • Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.

    Warner K Huh;Matthew Powell;Charles A Leath;J.Michael Straughn

  • Conservative Management of Stage I Endometrial Carcinoma after Surgical Staging

    J.Michael Straughn;Warner K. Huh;F.Joseph Kelly;Charles A. Leath

  • Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.

    Rebecca C. Arend;Angelina I. Londoño-Joshi;Rajeev S. Samant;Yonghe Li

Frequent Co-Authors

David T. Curiel
David T. Curiel Washington University in St. Louis
Gene P. Siegal
Gene P. Siegal University of Alabama at Birmingham
Akseli Hemminki
Akseli Hemminki University of Helsinki
Charles N. Landen
Charles N. Landen University of Virginia
William E. Grizzle
William E. Grizzle University of Alabama at Birmingham
Chien-Fu Hung
Chien-Fu Hung Johns Hopkins University
Albert F. LoBuglio
Albert F. LoBuglio University of Alabama at Birmingham
David E. Cohn
David E. Cohn The Ohio State University
Igor Dmitriev
Igor Dmitriev Washington University in St. Louis
Victor Krasnykh
Victor Krasnykh The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to multiple online degree options and nursing career pathways. For students seeking flexible, affordable alternatives, there are several accredited programs tailored to your needs and budget.

Many aspiring nurses start with cheap online nursing programs that offer solid foundational training at a lower cost. If you are a registered nurse looking to advance your career, consider cheap rn to bsn programs for bachelor’s-level credentials without financial strain.

Those aiming for the highest clinical roles can take advantage of cheapest dnp programs, which prepare nurses for leadership and specialized practice. Meanwhile, if your background isn’t in nursing but you want to pivot careers, direct entry msn programs for non-nurses online provide a streamlined path for non-nursing graduates.

With a variety of affordable online options available, students and professionals at any stage can find a program suited to their goals and budget.

Best Scientists Citing Ronald D. Alvarez

Trending Scientists

Recently Published Articles